share_log

Pfizer | 4: Statement of changes in beneficial ownership of securities-Officer Dolsten Mikael

SEC announcement ·  Feb 29 06:15
Summary by Futu AI
Mikael Dolsten, President of R&D at Pfizer Inc, was reported to have engaged in a transaction involving the company's stock on February 27, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The report did not provide information on the number of shares held by Dolsten after the action. As this information is crucial for investors, the lack of details might affect their ability to make fully informed decisions regarding their investments in Pfizer.
Mikael Dolsten, President of R&D at Pfizer Inc, was reported to have engaged in a transaction involving the company's stock on February 27, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The report did not provide information on the number of shares held by Dolsten after the action. As this information is crucial for investors, the lack of details might affect their ability to make fully informed decisions regarding their investments in Pfizer.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.